PARTHENON THERAPEUTICS is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Parthenon combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications. Parthenon is led by an experienced leadership team with extensive drug development experience and is backed by world-class investors.
View Top Employees from Parthenon TherapeuticsWebsite | http://www.parthenontx.com |
Employees | 37 (17 on RocketReach) |
Founded | 2019 |
Address | 40 Guest St, Boston, Massachusetts 02135, US |
Technologies |
JavaScript,
HTML,
PHP
+10 more
(view full list)
|
Industry | Biotechnology Research |
Looking for a particular Parthenon Therapeutics employee's phone or email?
Jeff Janotka is the Vice President, Head of Clinical Operations of Parthenon Therapeutics.
17 people are employed at Parthenon Therapeutics.
Parthenon Therapeutics is based in Boston, Massachusetts.